Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

71.4%

5 terminated/withdrawn out of 7 trials

Success Rate

28.6%

-57.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03029104Phase 2Terminated

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

Role: lead

NCT01189864Terminated

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

Role: lead

NCT01956474Phase 2Terminated

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Role: lead

NCT01024322Terminated

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Role: lead

NCT01097447Terminated

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)

Role: lead

NCT01739673Not ApplicableCompleted

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Role: lead

NCT01726283Completed

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

Role: lead

All 7 trials loaded